TY - JOUR
T1 - Expression of ret finger protein correlates with outcomes in endometrial cancer
AU - Tsukamoto, Hirohisa
AU - Kato, Takuya
AU - Enomoto, Atsushi
AU - Nakamura, Nobuhisa
AU - Shimono, Yohei
AU - Jijiwa, Mayumi
AU - Asai, Naoya
AU - Murakumo, Yoshiki
AU - Shibata, Kiyosumi
AU - Kikkawa, Fumitaka
AU - Takahashi, Masahide
PY - 2009/10
Y1 - 2009/10
N2 - Ret finger protein (RFP) is a nuclear protein with transcriptional repressive activity that is highly expressed in a variety of human and rodent tumor cell lines. We examined the expression of RFP in human endometrial cancer and assessed its clinical significance. Formalin-fixed, paraffin-embedded sections from endometrial cancer tissues were immunostained with the RFP antibody, and the staining intensity was evaluated. The clinicopathological factors examined were age, International Federation of Gynecology and Obstetrics stage, tumor grade, myometrial invasion, and pelvic lymph node metastasis. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. Of the 119 cancer tissues, 57 (47.9%) cases were positive for RFP immunoreactivity. RFP expression was not associated with any of the clinicopathological parameters examined. However, positive RFP expression significantly predicted poorer OS and PFS compared with negative expression (OS, P = 0.0011; PFS, P < 0.0001). In the multivariate analyses, positive RFP expression was an independent prognostic factor for survival in this study. RFP knockdown significantly impaired cancer cell migration and invasion in vitro with concomitant decreases of integrins β1 and α2. Positive RFP expression is a predictive marker for an unfavorable clinical outcome in patients with endometrial cancer. (Cancer Sci 2009; 100: 1895-1901).
AB - Ret finger protein (RFP) is a nuclear protein with transcriptional repressive activity that is highly expressed in a variety of human and rodent tumor cell lines. We examined the expression of RFP in human endometrial cancer and assessed its clinical significance. Formalin-fixed, paraffin-embedded sections from endometrial cancer tissues were immunostained with the RFP antibody, and the staining intensity was evaluated. The clinicopathological factors examined were age, International Federation of Gynecology and Obstetrics stage, tumor grade, myometrial invasion, and pelvic lymph node metastasis. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. Of the 119 cancer tissues, 57 (47.9%) cases were positive for RFP immunoreactivity. RFP expression was not associated with any of the clinicopathological parameters examined. However, positive RFP expression significantly predicted poorer OS and PFS compared with negative expression (OS, P = 0.0011; PFS, P < 0.0001). In the multivariate analyses, positive RFP expression was an independent prognostic factor for survival in this study. RFP knockdown significantly impaired cancer cell migration and invasion in vitro with concomitant decreases of integrins β1 and α2. Positive RFP expression is a predictive marker for an unfavorable clinical outcome in patients with endometrial cancer. (Cancer Sci 2009; 100: 1895-1901).
UR - http://www.scopus.com/inward/record.url?scp=70349585445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349585445&partnerID=8YFLogxK
U2 - 10.1111/j.1349-7006.2009.01278.x
DO - 10.1111/j.1349-7006.2009.01278.x
M3 - Article
C2 - 19650860
AN - SCOPUS:70349585445
SN - 1347-9032
VL - 100
SP - 1895
EP - 1901
JO - Cancer science
JF - Cancer science
IS - 10
ER -
